- Home
- PIM vs SLS Comparison
PIM vs SLS Comparison
Compare PIM & SLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PIM
- SLS
- Stock Information
- Founded
- PIM 1988
- SLS 2012
- Country
- PIM United States
- SLS United States
- Employees
- PIM N/A
- SLS N/A
- Industry
- PIM Finance Companies
- SLS Biotechnology: Pharmaceutical Preparations
- Sector
- PIM Finance
- SLS Health Care
- Exchange
- PIM Nasdaq
- SLS Nasdaq
- Market Cap
- PIM 161.4M
- SLS 165.6M
- IPO Year
- PIM N/A
- SLS N/A
- Fundamental
- Price
- PIM $3.33
- SLS $1.66
- Analyst Decision
- PIM
- SLS Strong Buy
- Analyst Count
- PIM 0
- SLS 1
- Target Price
- PIM N/A
- SLS $7.00
- AVG Volume (30 Days)
- PIM 57.5K
- SLS 2.8M
- Earning Date
- PIM 01-01-0001
- SLS 08-12-2025
- Dividend Yield
- PIM 8.28%
- SLS N/A
- EPS Growth
- PIM N/A
- SLS N/A
- EPS
- PIM 0.05
- SLS N/A
- Revenue
- PIM N/A
- SLS N/A
- Revenue This Year
- PIM N/A
- SLS N/A
- Revenue Next Year
- PIM N/A
- SLS N/A
- P/E Ratio
- PIM $63.80
- SLS N/A
- Revenue Growth
- PIM N/A
- SLS N/A
- 52 Week Low
- PIM $2.90
- SLS $0.77
- 52 Week High
- PIM $3.28
- SLS $2.27
- Technical
- Relative Strength Index (RSI)
- PIM 50.75
- SLS 41.18
- Support Level
- PIM $3.28
- SLS $1.75
- Resistance Level
- PIM $3.34
- SLS $1.96
- Average True Range (ATR)
- PIM 0.03
- SLS 0.12
- MACD
- PIM -0.00
- SLS -0.04
- Stochastic Oscillator
- PIM 62.50
- SLS 18.56
About PIM Putnam Master Intermediate Income Trust
Putnam Master Intermediate Income Trust is a closed-end fund. Its investment objective is to provide high current income and relative stability of net asset value. The fund pursues its goal by investing in U.S. high-grade, high-yield, and international fixed-income securities with limited maturities. The fund's portfolio includes the United States Government and agency mortgage obligations; mortgage-backed securities; corporate bonds and notes, and foreign government and agency bonds and notes.
About SLS SELLAS Life Sciences Group Inc.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.